Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma

Fig. 3

Comprehensive adverse event profiles among the three regimens (full-dose GC, dose-reduced GC, and GCa). The analysis was conducted for 97 patients with sufficient data (GCa, n = 32; full-dose GC, n = 41; dose-reduced GC, n = 24). Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, GC gemcitabine/cisplatin, GCa gemcitabine/carboplatin

Back to article page